{"id":904021,"date":"2025-11-03T08:30:16","date_gmt":"2025-11-03T13:30:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"modified":"2025-11-03T08:30:16","modified_gmt":"2025-11-03T13:30:16","slug":"monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","title":{"rendered":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BOSTON, Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OqTqKd6K6Eq0ShDW0nfwkxCmIP7UO7KpKQ4p7cHo3D8-fspXq_lY_8ZJFQPmWSqvkX-a5itiSgluV5CRRdoH1YmIUY_DKXtOIkNz8yTK1UkuG5sZ7yvVM_jL3_7cHBEx\" rel=\"nofollow\" target=\"_blank\"><u>Monte Rosa Therapeutics, Inc.<\/u><\/a> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences:<\/p>\n<ul type=\"disc\">\n<li>Guggenheim 2<sup>nd<\/sup> Annual Healthcare Innovation Conference (Boston, MA) \u2013 November 10, 2025, at 11:30 a.m. ET<\/li>\n<li>TD Cowen Immunology &amp; Inflammation Summit (virtual) \u2013 November 13, 2025, at 12:00 p.m. ET<\/li>\n<li>Jefferies Global Healthcare Conference in London \u2013 November 18, 2025, at 11:30 a.m. GMT<\/li>\n<li>Piper Sandler 37<sup>th<\/sup> Annual Healthcare Conference (New York, NY) \u2013 December 2, 2025, at 1:30 p.m. ET<\/li>\n<\/ul>\n<p>Webcasts of the fireside chats will be accessible via the \u201cEvents &amp; Presentations\u201d section of Monte Rosa\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-5onB7uzoZASC6hLApUQYidLXKKY83f7lRDxSPj3Just2wVn1ORKeDhedH26Df92yVThfh8ylKTpbnyEIh4rkSfaXvrgrNBrVlTY0S6rtQE=\" rel=\"nofollow\" target=\"_blank\">ir.monterosatx.com<\/a>, and archived versions will be made available for 30 days following the presentations.<\/p>\n<p>\n        <strong>About Monte Rosa<\/strong><br \/>\n        <br \/>Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa\u2019s QuEEN\u2122 (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry\u2019s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XXGZcXa-Ez8DKobgrQ5v8wym165qWTsuyl02kI0R1IopQpZhQOyfgcmv9P6P-m0lo5wFaA7lRUkNDIc5qTDVCpETi0yZGrRDQ3jLAE46gBE=\" rel=\"nofollow\" target=\"_blank\">www.monterosatx.com<\/a>.<\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Andrew Funderburk <br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2RiuwlcvsfCkLfDR18mrNWHf6HIotooBDwJpYfErS4-WogrpMUfh0P_93rbzaKJ1rkbIYqIxv1ooaioHk43qPsytu_4kwqYYVZe0jApxZ8I=\" rel=\"nofollow\" target=\"_blank\">ir@monterosatx.com<\/a><\/u><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Cory Tromblee, Scient PR<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hAkQXtZKLiuglDF7rxrjhp99QOKYD6tJa0TxB6-SZongu5lu_QjhNFQYSxVdzcpzC3VbmDyPlixfCrWr6ECSEu8-31S0b2o5uiQtmtDcbFU=\" rel=\"nofollow\" target=\"_blank\">media@monterosatx.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjA5MGQ0MmQtYjNhOS00YjA4LWJiMzItOTY4ZDFhOWRhZjM4LTEyMjEwOTgtMjAyNS0xMS0wMy1lbg==\/tiny\/Monte-Rosa-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, MA) \u2013 November 10, 2025, at 11:30 a.m. ET TD Cowen Immunology &amp; Inflammation Summit (virtual) \u2013 November 13, 2025, at 12:00 p.m. ET Jefferies Global Healthcare Conference in London \u2013 November 18, 2025, at 11:30 a.m. GMT Piper Sandler 37th Annual Healthcare Conference (New York, NY) \u2013 December 2, 2025, at 1:30 p.m. ET Webcasts of the fireside chats will be accessible via the \u201cEvents &amp; Presentations\u201d section of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904021","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, MA) \u2013 November 10, 2025, at 11:30 a.m. ET TD Cowen Immunology &amp; Inflammation Summit (virtual) \u2013 November 13, 2025, at 12:00 p.m. ET Jefferies Global Healthcare Conference in London \u2013 November 18, 2025, at 11:30 a.m. GMT Piper Sandler 37th Annual Healthcare Conference (New York, NY) \u2013 December 2, 2025, at 1:30 p.m. ET Webcasts of the fireside chats will be accessible via the \u201cEvents &amp; Presentations\u201d section of &hellip; Continue reading &quot;Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T13:30:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2025-11-03T13:30:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"wordCount\":264,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\",\"name\":\"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=\",\"datePublished\":\"2025-11-03T13:30:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Boston, MA) \u2013 November 10, 2025, at 11:30 a.m. ET TD Cowen Immunology &amp; Inflammation Summit (virtual) \u2013 November 13, 2025, at 12:00 p.m. ET Jefferies Global Healthcare Conference in London \u2013 November 18, 2025, at 11:30 a.m. GMT Piper Sandler 37th Annual Healthcare Conference (New York, NY) \u2013 December 2, 2025, at 1:30 p.m. ET Webcasts of the fireside chats will be accessible via the \u201cEvents &amp; Presentations\u201d section of &hellip; Continue reading \"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T13:30:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2025-11-03T13:30:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"wordCount":264,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","name":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=","datePublished":"2025-11-03T13:30:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Njg1MSM3MjM3ODg1IzIyMDk1NDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904021"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904021\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}